- Home
- MDRR vs CHRO Comparison
MDRR vs CHRO Comparison
Compare MDRR & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- CHRO
- Stock Information
- Founded
- MDRR 2015
- CHRO 2002
- Country
- MDRR United States
- CHRO United States
- Employees
- MDRR N/A
- CHRO N/A
- Industry
- MDRR Real Estate Investment Trusts
- CHRO
- Sector
- MDRR Real Estate
- CHRO
- Exchange
- MDRR Nasdaq
- CHRO Nasdaq
- Market Cap
- MDRR 13.9M
- CHRO 11.3M
- IPO Year
- MDRR 2018
- CHRO 2024
- Fundamental
- Price
- MDRR $12.56
- CHRO $1.68
- Analyst Decision
- MDRR
- CHRO Strong Buy
- Analyst Count
- MDRR 0
- CHRO 1
- Target Price
- MDRR N/A
- CHRO N/A
- AVG Volume (30 Days)
- MDRR 4.9K
- CHRO 104.9K
- Earning Date
- MDRR 03-05-2025
- CHRO 03-04-2025
- Dividend Yield
- MDRR 1.71%
- CHRO N/A
- EPS Growth
- MDRR N/A
- CHRO N/A
- EPS
- MDRR N/A
- CHRO N/A
- Revenue
- MDRR $9,916,929.00
- CHRO N/A
- Revenue This Year
- MDRR N/A
- CHRO N/A
- Revenue Next Year
- MDRR N/A
- CHRO N/A
- P/E Ratio
- MDRR N/A
- CHRO N/A
- Revenue Growth
- MDRR N/A
- CHRO N/A
- 52 Week Low
- MDRR $10.60
- CHRO $0.45
- 52 Week High
- MDRR $15.00
- CHRO $4.84
- Technical
- Relative Strength Index (RSI)
- MDRR 49.84
- CHRO 50.49
- Support Level
- MDRR $12.30
- CHRO $1.59
- Resistance Level
- MDRR $13.31
- CHRO $1.99
- Average True Range (ATR)
- MDRR 0.48
- CHRO 0.29
- MACD
- MDRR 0.06
- CHRO -0.06
- Stochastic Oscillator
- MDRR 27.34
- CHRO 41.44
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing, and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its principal objectives include sourcing value-added Investments in markets in which it maintains deep industry relationships and local market knowledge and the creation of value for stockholders by utilizing its relationships and local knowledge of commercial real estate investment, management, and disposition.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.